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Abstract
Background: Previous reports have shown an antiproliferative effect of the synthetic, 3-thia fatty acid
tetradecylthioacetic acid (TTA) on different cancer cells in vitro and in vivo. The mechanisms behind the observed
effects are poorly understood. We therefore wanted to explore the molecular mechanisms involved in TTA-induced
growth inhibition of the human colon cancer cell line SW620 by gene expression profiling.
Methods: An antiproliferative effect of TTA on SW620 cells in vitro was displayed in real time using the xCELLigence
System (Roche). Affymetrix gene expression profiling was performed to elucidate the molecular mechanisms behind
the antiproliferative effect of TTA. Changes in gene expression were verified at protein level by western blotting.
Results: TTA reduced SW620 cell growth, measured as baseline cell index, by 35% and 55% after 48 h and 72 h,
respectively. We show for the first time that TTA induces an endoplasmic reticulum (ER) stress response in cancer cells.
Gene expression analysis revealed changes related to ER stress and unfolded protein response (UPR). This was verified
at protein level by phosphorylation of eukaryote translation initiation factor 2 alpha (eIF2a) and downstream up-
regulation of activating transcription factor 4 (ATF4). Transcripts for positive and negative cell cycle regulators were
down- and up-regulated, respectively. This, together with a down-regulation of Cyclin D1 at protein level, indicates
inhibition of cell cycle progression. TTA also affected transcripts involved in calcium homeostasis. Moreover, mRNA and
protein level of the ER stress inducible C/EBP-homologous protein (CHOP), Tribbles homolog 3 (Drosophila) (TRIB3) and
CCAAT/enhancer binding protein beta (C/EBPb) were enhanced, and the C/EBPb LIP/LAP ratio was significantly
increased. These results indicate prolonged ER stress and a possible link to induction of cell death.
Conclusion: We find that TTA-induced growth inhibition of SW620 cells seems to be mediated through induction
of ER stress and activation of the UPR pathway.
Keywords: Cell cycle, Colon cancer, Docosahexaenoic acid, Endoplasmic reticulum stress, Gene expression analysis,
Phosphorylated eIF2α, Tetradecylthioacetic acid, Thia fatty acids, Unfolded protein response
Background
Colon cancer is one of the most common incident can-
cers across Europe [1]. There is an urgent need for find-
ing novel, alternative or supplementary cancer
treatments. Polyunsaturated fatty acids (PUFAs) are able
to inhibit growth of both colon and several other types
of cancer cells in vitro and in vivo ([2-5] and reviewed
in [6-8]). During the last two decades, chemical modi-
fied fatty acid (FA) analogs have been produced in an
attempt to achieve FAs having increased metabolic sta-
bility and more selective and targeted effects (reviewed
in [9]). Among these is the bioactive, saturated 3-thia
FA tetradecylthioacetic acid (TTA). TTA has been
shown to have both a cardioprotective effect, as well as
an antiproliferative effect on cancer cells (reviewed in
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[11,12], leukemia [13-16] and colon cancer cell lines
[11,17] in vitro and in vivo, and hepatoma [18] and
breast cancer cells [19] in vitro.T T As e e m st ob em o r e
potent in reducing cell growth compared with the
omega-3 (n-3) PUFAs eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) [20]. A diet containing
TTA has also resulted in increased vascularisation of
colon cancer xenografts in mice [17] and improved the
survival of mice having leukemia xenografts [11,14].
TTA food supplementation seems to be generally well
tolerated by healthy persons [15,21], and TTA therefore
may have a potential in cancer treatment alone or in
combination with other therapies.
The structure of TTA is equal to the saturated palmi-
tic acid (PA), except that TTA has a sulphur atom
inserted at the third position in the carbon chain [19].
The sulphur atom makes TTA resistant to mitochon-
drial b-oxidation and probably contributes substantial to
its biological effects (reviewed in [10]). TTA is capable
of reducing the growth of cancer cells that are not
growth inhibited by PA [17,20,22]. TTA is degraded
relatively slowly to various dicarboxylic acids via ω-oxi-
dation and sulphur oxidation in the endoplasmic reticu-
l u m( E R )a n ds u b s e q u e n tb-oxidation in the
peroxisomes. Except from blocked mitochondrial b-oxi-
dation, the chemical properties and metabolism of TTA
resembles those of normal FAs. TTA is activated by
binding to coenzyme A and incorporated into various
lipids, especially phospholipids (reviewed in [10,23]).
Before any recommendations regarding use of TTA in
cancer treatment can be given, it’s important to eluci-
date the molecular mechanisms underlying the growth
inhibitory effect of TTA. In some, but not all, cancer
cells, TTA inhibits cancer cell growth via increased lipid
peroxidation and oxidative stress [12], or partly via acti-
vation of peroxisome proliferator activated receptor
gamma [22]. Also, TTA has been shown to induce
apoptosis in several glioma [12,13] and leukemia cell
lines [13,14]. Induction of apoptosis seems to be related
to effects on mitochondria. TTA can induce a decrease
in mitochondrial membrane potential [13,24] and lead
to release of cytochrome C (cyt C) and a reduction in
mitochondrial glutathione, the latter indicating a selec-
tive modulation of the mitochondrial redox equilibrium
[13]. Most of the biological effects of TTA assumed to
be implicated in mediating the inhibitory effect of TTA
on cancer cells do not seem to be specific for TTA,
since they also are assumed to be involved in the growth
inhibitory effect of other FAs like n-3 PUFAs [25-27].
We have previously shown that TTA inhibits the
growth of SW620 human colon cancer cells in vitro and
in vivo [17]. SW620 cell growth is also inhibited by n-3
PUFAs [2,4]. By using gene expression analysis, we
found that DHA induces extensive changes in the
expression of transcripts involved in biological pathways
like ER stress and unfolded protein response (UPR),
protein degradation, Ca
2+ homeostasis, cell cycle pro-
gression and apoptosis [28]. Others have found that PA
also can induce ER stress in human [29] and rat cancer
cells [30].
The main functions of ER are protein synthesis and
folding, lipid synthesis and maintenance of Ca
2+ home-
ostasis. Disruption of these processes causes accumula-
tion of misfolded proteins in ER lumen, leading to ER
stress and activation of the cellular stress response UPR.
The purpose of UPR is to restore cell homeostasis and
promote cell survival, but during prolonged ER stress,
apoptosis may be activated. During ER stress, one of the
three ER stress sensors; eukaryotic translation initiation
factor 2 alpha (eIF2a) kinase 3 (EIF2AK3/PERK) is
known to phosphorylate eIF2a, thereby attenuating glo-
bal protein synthesis to reduce the protein load of ER.
Reduced synthesis of e.g. cyclin D1 promotes cell cycle
arrest, creating time to cope with the stress. However,
translation of certain mRNAs is allowed, like mRNAs
for activating transcription factor 4 (ATF4) and its
downstream target C/EBP-homologous protein (CHOP)
[31,32]. CHOP, which is also regulated by X-box bind-
ing protein 1 (XBP-1) (reviewed in [33]), promotes
apoptosis by down-regulating anti-apoptotic factors like
B-cell lymphoma 2 (Bcl-2) [34] and up-regulating pro-
apoptotic factors like the Bcl-2-interacting protein Bim
[35].
During ER stress XBP-1 also activates the transcrip-
tion factor CCAAT/enhancer binding protein beta (C/
EBPb) [36], which participates in regulation of differen-
tiation, cell growth, cell survival and apoptosis [37,38].
Human C/EBPb is mainly expressed as two 46 and 42
kDa liver enriched activator protein isoforms (LAP and
LAP*) and a 20 kDa liver enriched inhibitor protein iso-
form (LIP) [39], which are synthesized from different
AUG start codons within the C/EBPb mRNA [40]. Since
LIP lacks a transcription activation domain [41] and
suppresses the transactivation by LAP, the LIP/LAP
ratio influences on the extent of C/EBPb-activated tran-
scription [40].
LIP has been shown to decrease during early ER
stress, and increase during prolonged ER stress, causing
an increase in the LIP/LAP ratio [42]. Increased LIP
seems to be essential for CHOP-induced apoptosis,
since heterodimerization of LIP with CHOP promotes
nuclear translocation of CHOP and pro-apoptotic gene
regulation by CHOP [43]. In addition, CHOP-C/EBPb
[44] and CHOP-ATF4 [45] heterodimeres up-regulate
the pro-apoptotic pseudo-kinase Tribbles homolog 3
(Drosophila) (TRIB3), which can promote apoptosis by
inhibiting the anti-apoptotic kinase Akt [46] and the
Lundemo et al. Lipids in Health and Disease 2011, 10:190
http://www.lipidworld.com/content/10/1/190
Page 2 of 12transcription factor nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-B) [47]. CHOP- and
TRIB3-promoted cell death might be accompanied by
the ER stress-induced caspase 4 (CASP4) and calpains
[32,48,49].
In this report we have used Affymetrix gene expres-
sion analysis to search for possible molecular mechan-
isms underlying the growth inhibitory effect of TTA on
SW620 cells in vitro.T h er e s u l t si n d i c a t et h a tT T A
reduces SW620 cell growth through activation of ER
stress and UPR, by a similar mechanism as observed
after treatment with DHA [28].
Results
TTA reduces growth of SW620 cells
In accordance with previous results [17], we verified a
growth inhibitory effect of TTA (75 μM) on SW620
colon cancer cells by cell counting (data not shown) and
by measuring the growth real time by using the xCELLi-
gence System (Roche) (Figure 1A). The SW620 growth
curve, which is presented as baseline cell index, showed
that TTA (75 μM) significantly reduced the baseline cell
index by 35% and 55% after 48 h and 72 h, respectively,
compared to the control (Figure 1B).
TTA induces extensive changes at mRNA level indicating
ER stress and UPR
In an attempt to unravel the mechanisms underlying the
growth-inhibiting effect of TTA, SW620 cells were culti-
vated in the absence or presence of 75 μMT T Af o r2 4
h, followed by gene expression profiling. Differentially
expressed transcripts are presented and listed by full
and short names in Table 1 and Additional file 1.
After incubation with TTA, the transcription level of
several genes involved in ER stress and UPR were
affected. The ER stress sensors inositol-requiring
enzyme 1 (IRE1) and activating transcription factor 6
(ATF6), and downstream targets of these, like XBP-1,
were up-regulated (Table 1). However, most changes in
the ER stress signaling pathway were found downstream
of PERK. Phosphorylation of eIF2a by PERK is a hall-
mark of ER stress (reviewed in [31]). After TTA treat-
ment, phosphorylated eIF2a (eIF2a-P) was found
significantly increased after 6 h and 24 h (Figure 2A).
Phosphorylation of eIF2a induces transcription of
ATF4 and its downstream targets, like ATF3, CHOP,
growth arrest and DNA-damage-inducible 34
(GADD34), TRIB3 [50,51] and heme oxygenase 1
(HMOX1) [52]. All these transcripts were up-regulated
upon TTA treatment (Table 1). Moreover, the protein
levels of ATF4, CHOP (Figure 2A) and TRIB3 (Figure
2B) were also increased. ATF4 is known to induce genes
involved in amino acid synthesis, and several transcripts
involved in amino acid synthesis and transport were also
up-regulated (Table 1 and Additional file 1).
When UPR is activated, cells try to up-regulate the
folding capacity e.g. through up-regulation of chaper-
ones and heat shock proteins (Hsps) [31]. Transcripts of
the folding machinery were found to be up-regulated in
the SW620 cells after incubation with TTA. These
include prefoldin 2 (PFDN2), DnaJ (HSP40) homolog,
subfamily B, member 2 (DNAJB2), DNAJB14, DnaJ
Figure 1 Real time monitoring of TTA-induced growth inhibition of SW620 cells. SW620 colon cancer cells were seeded in 16 well E-
plates. After ~24 h, TTA (75 μM) or NaOH (control) were added. Cell growth was monitored using the xCELLigence RTCA DP Instrument (Roche).
(A) SW620 cell growth presented as baseline cell index from one representative experiment. (B) Average baseline cell index (± SD) of TTA-treated
cells, presented as percent of control, at indicated time points. Mean was calculated from at least two duplicate measurements in four
independent experiments. * Significantly different from control (one-tailed Student’s t-test, P < 0.05).
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Gene Symbol Affymetrix
ID
Refseq NCBI
ID
Transcript name SW620
Fold
Change
24 h
ER stress and unfolded protein response
ATF3 202672_s_at NM_001030287
NM_001040619
NM_001674
NM_004024
Activating transcription factor 3 3.5
ATF4 200779_at NM_001675
NM_182810
Activating transcription factor 4 1.7
ATF6 217550_at
231927_at
203952_at
NM_007348 Activating transcription factor 6 1.5
1.3
1.2
CEBPB 212501_at NM_005194 CCAAT/enhancer binding protein (C/EBP), beta 3.2
CHOP/DDIT3 209383_at NM_001130101
NM_001130102
NM_004083
NM_005693
DNA-damage-inducible transcript 3 2.7
GADD34 37028_at
202014_at
NM_014330 Growth arrest and DNA-damage-inducible 34 2.0
2.0
IRE1/ERN1 235745_at NM_001433 Inositol-requiring enzyme 1/Endoplasmic reticulum to nucleus signaling 1 1.7
NRF2/NFE2L2 201146_at NM_001145412
NM_001145413
NM_006164
Nuclear factor (erythroid-derived 2)-like 2 1.3
TRIB3 1555788_a_at
218145_at
NM_021158 Tribbles homolog 3 (Drosophila) 5.1
4.9
XBP1 242021_at
200670_at
NM_001079539
NM_005080
X-box binding protein 1 1.2
1.6
Chaperones/Protein folding/Unfolded protein response/Protein degradation/Amino acid synthesis
ASNS 205047_s_at NM_001673
NM_133436
NM_183356
Asparagine synthetase 4.8
CREB3L2 212345_s_at NM_194071 cAMP responsive element binding protein 3-like 2 1.4
CREB3L3 234361_at NM_032607 cAMP responsive element binding protein 3-like 3 3.0
DNAJB2 202500_at NM_001039550
NM_006736
DnaJ (Hsp40) homolog, subfamily B, member B2 1.3
DNAJB14 222850_s_at NM_001031723 DnaJ (Hsp40) homolog, subfamily B, member B14 1.2
DNAJC24 242562_at NM_181706 DnaJ (Hsp40) homolog, subfamily C, member 24 1.4
EDEM1 203279_at NM_014674 ER degradation enhancer, mannosidase alpha-like 1 1.3
EDEM3 220342_x_at NM_025191 ER degradation enhancer, mannosidase alpha-like 3 1.2
ERO1LB 231944_at NM_019891 ERO1-like beta (S. cerevisiae) 1.3
HMOX1/HSP32 203665_at NM_002133 Heme oxygenase (decycling) 1 1.6
HSPA13 202557_at
202558_s_at
NM_006948 Heat shock 70kDa protein 13 1.4
1.7
PDIA2 206691_s_at NM_006849 Protein disulfide isomerase family A, member 2 1.2
PFDN2 218336_at NM_012394 Prefoldin 2 1.4
PSMB1 214289_at NM_002793 Proteasome subunit, beta type, 1 1.3
SQSTM1 201471_s_at
213112_s_at
239004_at
244804_at
NM_001142298
NM_001142299
NM_003900
Sequestosome 1 2.1
3.1
1.3
2.1
UBE2B 239163_at NM_003337 Ubiquitin-conjugating enzyme E2B (RAD6 homolog) 1.5
SEC61A2 219499_at
228747_at
NM_001142627
NM_001142628
NM_018144
Sec61 alpha 2 subunit (S. cerevisiae) 1.3
1.2
Lundemo et al. Lipids in Health and Disease 2011, 10:190
http://www.lipidworld.com/content/10/1/190
Page 4 of 12Table 1 Gene expression results (Continued)
SEC61B 244700_at NM_006808 Sec61 beta subunit 1.6
SEC63 201914_s_at
201915_s_at
201916_s_at
NM_007214 SEC63 homolog (S. cerevisiae) 1.3
1.2
1.3
Ca2
+ homeostasis, signaling and transport
ATP2B4/PMCA4 205410_s_at
212135_s_at
212136_at
NM_001001396
NM_001684
ATPase, Ca
2+ transporting, plasma membrane 4 1.5
2.7
5.4
CAPN1 232012_at NM_005186 Calpain 1, (mu/I) large subunit 1.4
CAPN2 208683_at
214888_at
NM_001146068
NM_001748
Calpain 2, large subunit 1.4
1.8
CAPN5 205166_at NM_004055 Calpain 5 1.4
HERPUD1 217168_s_at NM_001010989
NM_001010990
NM_014685
Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like
domain member 1
1.9
ITPR1 244090_at — Inositol 1,4,5-triphosphate receptor, type 1 1.3
ITPR3 201187_s_at
201188_s_at
201189_s_at
NM_002224 Inositol 1,4,5-triphosphate receptor, type 3 1.3
1.5
1.5
PLCD3 234971_x_at
1552476_s_at
NM_133373 Phospholipase C, delta 3 1.3
1.3
S100A10 200872_at
238909_at
NM_002966 S100 calcium binding protein A10 1.2
2.4
S100P 204351_at NM_005980 S100 calcium binding protein P 4.9
STC2 203438_at
203439_s_at
NM_003714 Stanniocalcin 2 2.1
2.7
Cell cycle/
Apoptosis
ATF5 204998_s_at
204999_s_at
NM_012068 Activating transcription factor 5 1.5
1.7
AURKA 208080_at NM_003600
NM_198433
NM_198434
NM_198435
NM_198436
NM_198437
Aurora kinase A -1.3
BIRC5 202094_at
202095_s_at
210334_x_at
NM_001012270
NM_001012271
NM_001168
Baculoviral IAP repeat-containing 5/Survivin -1.7
-1.3
-1.3
CASP4 213596_at NM_001225
NM_033306
Caspase 4 1.4
CCNA2 203418_at
213226_at
NM_001237 Cyclin A2 -1.2
-1.2
CCND3 201700_at NM_001136017
NM_001136125
NM_001136126
NM_001760
Cyclin D3 -2.0
CCNE1 213523_at NM_001238
NM_057182
Cyclin E1 -1.3
CCNE2 205034_at
211814_s_at
NM_057749 Cyclin E2 -2.9
-3.1
CCNF 204827_s_at NM_001761 Cyclin F -1.2
CDC2/CDK1 203214_x_at NM_001130829
NM_001786
NM_033379
Cell division cycle 2, G1 to S and G2 to M -1.2
CDK2 204252_at
211804_s_at
NM_001798
NM_052827
Cyclin-dependent kinase 2 -1.3
-1.4
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heat shock protein 13 (HSPA13), HSP32 (HMOX1) and
hypoxia up-regulated 1 (HYOU1) (Table 1 and Addi-
tional file 1). Protein disulfide isomerase family A, mem-
ber 2 (PDIA2) and ERO1-like beta (ERO1LB), which are
known to catalyze protein folding [31,53], were also up-
regulated (Table 1). However, some DnaJ (Hsp40)
homolog subfamily members and Hsps were also found
to be down-regulated (Additional file 1).
During ER stress, improperly folded proteins are
transferred to ER degradation enhancer, mannosidase
alpha-like protein (EDEM) and translocated to cytosol
for proteasomal degradation; a process called ER asso-
ciated degradation (ERAD) [31]. EDEM1 and EDEM3,
in addition to several proteasomal subunits and ubiqui-
tin-related transcripts, were up-regulated upon TTA
treatment. Also, proteasome subunit, beta type, 1
(PSMB1), ubiquitin-conjugating enzyme E2B (RAD6
homolog) (UBE2B) and cullin1 (CUL1) were up-regu-
lated (Table 1 and Additional file 1). In addition, TTA
also up-regulated sequestosome 1 (SQSTM1), which is
able to sequester and shuttle polyubiquitinated, mis-
folded proteins to the proteasome (reviewed in [54])
(Table 1). Moreover, TTA up-regulated transcripts for
parts of the ER translocation machinery which trans-
ports proteins to the cytosol, like Sec61 alpha 2 subunit
(SEC61A2), Sec61 beta subunit (SEC61B) and SEC63
homolog (SEC63) (Table 1).
TTA affects Ca
2+ homeostasis
Another indication of an ER stress condition in SW620
cells treated with TTA is the altered expression of tran-
scripts coding for proteins involved in Ca
2+ homeostasis.
The more than 5-fold up-regulation of ATPase, Ca
2
+-transporting, plasma membrane 4 (ATP2B4/PMCA4)
might indicate the presence of a high Ca
2+ concentra-
tion in the cytosol (Table 1). A possible high Ca
2+ level
in the cytosol may be part of the ER stress response,
with Ca
2+ leaking from ER through the up-regulated IP3
receptors, type 1 and 3 (ITPR1 and 3, Table 1). We also
found Phospholipase C D3 (PLCD3), which is known to
participate in the generation of IP3 [55], to be up-regu-
lated at mRNA level after TTA-treatment (Table 1).
Among other important Ca
2+-related transcripts, we found
several S100 Ca
2+ binding proteins to be differentially
expressed after TTA-treatment, e.g. S100P and S100A10
were up-regulated (Table 1 and Additional file 1). Also, TTA
caused up-regulation of Stanniocalcin 2 (STC2), which is
induced downstream of PERK and critical for survival after
UPR [56]. TTA further up-regulated homocysteine-inducible
endoplasmic reticulum stress-inducible ubiquitin-like
domain member 1 (HERPUD1) (Table 1), which is known
to counteract Ca
2+ disturbances during ER stress [57].
Effect of TTA on cell cycle
TTA affected the mRNA level of several cell cycle tran-
scripts, most of them having rather small fold change
Table 1 Gene expression results (Continued)
CDK4 202246_s_at NM_000075 Cyclin-dependent kinase 4 -1.4
CDK5 204247_s_at NM_001164410
NM_004935
Cyclin-dependent kinase 5 -1.5
CDK6 224847_at
224848_at
224851_at
243000_at
NM_001145306
NM_001259
Cyclin-dependent kinase 6 -1.4
-1.5
-1.3
-1.3
CDKN2A 211156_at NM_000077
NM_058195
NM_058197
Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 1.3
CDKN2B 207530_s_at
236313_at
NM_004936
NM_078487
Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 1.5
2.0
CDKN2D 210240_s_at NM_001800
NM_079421
Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 1.2
CUL1 238509_at NM_003592 Cullin 1 1.4
KLF4 220266_s_at
221841_s_at
NM_004235 Kruppel-like factor 4 (gut) 1.9
2.4
PDCD4 202731_at
212593_s_at
NM_014456
NM_145341
Programmed cell death 4 (neoplastic transformation inhibitor) 1.3
1.3
PDCD6 222152_at
222380_s_at
NM_013232 Programmed cell death 6 1.3
1.3
SFN 33322_i_at
33323_r_at
209260_at
NM_006142 Stratifin 1.6
1.7
1.6
Significantly differentially expressed transcripts in SW620 treated with TTA (75 μM) for 24 h as determined by Affymetrix microarray analysis (P < 0.05).
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lated and negative regulators were up-regulated, as out-
lined below.
The cell cycle is known to be positively regulated by
cyclins (CCNs) and cyclin dependent kinases (CDKs).
The mRNA level of cyclin D3 (CCND3), but not cyclin
D1, was down-regulated upon TTA treatment (Table 1).
However, the protein level of cyclin D1 was significantly
decreased after incubation with TTA (Figure 2A). More-
over, transcripts for CCNA2, CCNE1, CCNE2, CCNF,
CDK1/CDC2, CDK2, CDK4, CDK5 and CDK6 were
down-regulated (Table 1), indicating inhibition of cell
cycle progression. The CDK4 inhibitors CDK inhibitor
2A (CDKN2A), CDKN2B and CKDN2D, which are nega-
tive regulators of cell cycle, were increased (Table 1). In
addition, the tumor suppressor programmed cell death 4
(PDCD4), which is able to reduce the protein level of
CDK4 [58], and PDCD6 were up-regulated (Table 1).
Other important cell cycle related transcripts that
were up-regulated by TTA were ATF5, stratifin (SFN/
14-3-3 sigma) and kruppel like factor 4 (KLF4) (Table
1). TTA also induced down-regulation of aurora kinase
A (AURKA) and survivin/baculoviral IAP repeat-con-
taining 5 (BIRC5) (Table 1).
TTA changes expression of transcripts involved in ER
stress-related apoptosis
Transcripts related to ER stress-induced apoptosis were
also up-regulated upon TTA treatment. In addition to
the up-regulation of CHOP and TRIB3, TTA also
increased transcription of CASP4, calpain 1, large subu-
nit (CAPN1), CAPN2 and CAPN5 (Table 1).
The C/EBPb LIP isoform is known to augment ER
stress-induced cell death by interfering with the expres-
sion of TRIB3 [59]. C/EBPb (CEBPB) was up-regulated
3.2-fold at mRNA level (Table 1) after TTA treatment.
Figure 2 TTA induces proteins involved in ER stress and UPR. SW620 cells were treated with TTA (75 μM) or NaOH (control) for indicated
time periods, and proteins were quantified by western blotting. (A) Analysis of eIF2a-P and Cyclin D1 from cytosolic protein extracts and ATF4
and CHOP from nuclear protein extracts. (B) Analysis of TRIB3 and the C/EBPb protein isoforms LAP (45 kDa) and LIP (20 kDa) from nuclear
protein extracts. Blots were quantified, and band intensities normalized relative to the respective loading control; b-actin (Cyclin D1), Lamin
(nuclear extracts) or total level of eIF2a (eIF2a-P), to adjust for unequal protein loading within the membranes. Band intensities were related to
the 24 h control band to adjust for differences in signal intensities between the membranes, except for TRIB3 where the band intensities are
related to the 24 h TTA band (not expressed in control). Quantified results show mean fold change (± SD) of TTA-samples relative to control at
indicated time periods for three independent experiments. One representative blot is shown. * Significantly different from control (one-tailed
Student’s t-test, P < 0.05).
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forms; a highly expressed4 5k D aL A Pi s o f o r ma n da
lower expressed 20 kDa LIP isoform. The 42 kDa LAP*
isoform was only found in very low amounts (Figure
2B). TTA did not affect the level of LAP, but induced a
significant 6.9- and 11.2-fold induction of LIP after 24
and 48 h, respectively (Figure 2B). The accumulation of
LIP at these time points caused a significant 6.6- and
13.3-fold increase in the LIP/LAP ratio after 24 h and
48 h, respectively, compared to control cells.
During ER stress, cAMP responsive element binding
protein 3-like 2 and 3 (CREB3L2 and CREB3L3) are
induced in order to attenuate ER stress-induced cell
death [60]. These transcripts were also up-regulated
(Additional file 1).
Discussion
Several studies have shown that TTA inhibits the
growth of various cancer cells in vitro and in vivo
[13,20,22]. We have previously shown that TTA inhibits
DNA synthesis in SW620 human colon cancer cells in a
time- and dose-dependent manner [17], and the growth
inhibitory effect of TTA on this cell line was confirmed
in the current study by xCELLigence proliferation assay.
This assay monitors cell growth real time by measuring
changes in electric impedance between two golden elec-
trodes embedded in the bottom of the cell culture wells.
The impedance, which is converted to a cell index
value, is directly proportional to the number of cells and
also reflects the cells’ viability, morphology and adhesion
strength [61]. The baseline cell index declined compared
to the control from approximately 20 hours after TTA-
supplementation. Previous studies have indicated that
TTA affects multiple biochemical pathways that might
play a role in its growth-limiting effect on different can-
cer cells. However, the exact mechanisms are not yet
clear.
This is the first study demonstrating that TTA is able
to induce ER stress in cancer cells. Transcripts involved
in ER stress and downstream of all three ER stress sen-
sors, like ATF6, IRE1, XBP-1 and ATF4, were found to
be differentially expressed after treating SW620 cells
with TTA. Also, the increased expression of Hsps and
DNAJs indicates that the cells try to increase their pro-
tein folding capacity. The up-regulation of EDEM1 and
EDEM3, SQSTM1, proteasomal subunits and ubiquitin-
related transcripts indicates activation of ERAD.
The PERK branch of UPR was found to be activated,
supported by the increased protein level of eIF2a-P and
ATF4, as well as up-regulation of several downstream
targets of ATF4, like ATF3, ASNS, CHOP and TRIB3,
at mRNA level. CHOP and TRIB3, also induced at pro-
tein level, are known to link ER stress to ER stress-
induced cell death (reviewed in [32]). The enhanced
level of these proteins and transcripts for CASP4 and
calpains indicates that TTA causes prolonged ER stress
and direct the cell fate towards induction of death. We
have previously shown that DHA induces ER stress with
increased eIF2a-P, ATF4 and CHOP in the same cell
line [28,62]. We also found HL-60 leukemia cells to
induce ER stress upon EPA treatment [63].
In SW620 cells, TTA up-regulated the C/EBPb LIP
isomer, while LAP was unchanged. LIP is capable of
modulating the ER stress response by augmenting cell
death, e.g. by enhancing the activity of CHOP [43]. On
the contrary, LAP may attenuate ER stress and ER stress
induced cell death by inhibiting CHOP [59,64]. How-
ever, Li et al. found that LAP modulated the ER stress
response by enhancing the expression of pro-apoptotic
genes. They also proposed that the ER stress response
may be modulated by regulation of the LIP/LAP ratio
[42]. We found this ratio to be increased after 24 and
48 h of TTA treatment, supporting the assumption that
TTA causes prolonged ER stress and a switch towards
induction of cell death. Even if C/EBPb mRNA was up-
regulated, we only found an increase of LIP at protein
level. Different regulation of LIP and LAP might be
explained by different synthesis and degradation rates of
these isomers [42].
Our results also indicate that TTA affects several tran-
scripts involved in cell cycle progression. Transcripts
involved in regulation of both the G1/S and G2/M
phases were differentially expressed. In general, positive
cell cycle regulators (like CDKs, cyclins, AURKA and
survivin) were down-regulated, and negative cell cycle
regulators (like ATF5, SFN and KLF4) were up-regu-
lated, which indicates a stop in the cell cycle progres-
sion. We have previously demonstrated that DHA
treatment of the SW620 cells affects several cell cycle
transcripts and proteins like CDKs, cyclins and survivin
etc. [62] and arrests the cells in the G2/M phase of the
cell cycle [2]. Brewer et. al. stated that cell cycle arrest
might be induced during ER stress to prevent cells from
completing cell division when the conditions are com-
promising proper folding and assembly of proteins [65].
TTA also seems to induce changes in expression of
transcripts involved in maintenance of Ca
2+ homeosta-
sis. The ER lumen contains a high Ca
2+ concentration,
and induction of ER stress may either come from and/
or culminate with a release of Ca
2+ from the ER
(reviewed in [66,67]). ER stress-accompanied changes in
the Ca
2+ metabolism may lead to a pro-apoptotic signal
via the mitochondria [66]. We have previously shown
t h a tD H Aa n dE P Aa f f e c tC a
2+ homeostasis in cancer
cells [28,63]. Apoptosis has been observed in other can-
cer cells treated with TTA [13,22], and it has been pro-
posed that this effect is mediated via mitochondrial
alterations, such as decrease in mitochondrial membrane
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may be involved in the regulation of mitochondrial
stress genes like TRIB3 [44] in response to accumulation
of unfolded proteins in mitochondria [68]. Their up-reg-
ulation by TTA may indicate that the SW620 cells are
undergoing a mitochondrial stress after TTA treatment.
Madsen et al. found TTA to be incorporated mainly
into phospholipids in liver after TTA supplementation
to rats [69]. The inner mitochondrial membrane phos-
pholipid cardiolipin (CL) is essential for the function of
several mitochondrial protein complexes. It interacts
with mitochondrial Cyt C, which might utilize reactive
oxygen species and cause oxidation of CL. Oxidized CL
is required for release of pro-apoptotic factors like Cyt
C to cytosol [70]. Enrichment of EPA and DHA in CL
isolated from colonic mucosa in rats fed fish oil or EPA/
DHA ethyl esters might result in high susceptibility to
lipid peroxidation due to the FAs’ high degree of unsa-
turation. This may trigger release of pro-apoptotic fac-
tors from mitochondria (reviewed in [71]). Decreased
synthesis of CL has also been related to Cyt C release
from mitochondria during PA-induced apoptosis
(reviewed in [9]). It remains to be investigated if this is
the case with TTA.
Conclusions
TTA induces extensive changes in the expression of
genes involved in several biological pathways. TTA
causes accumulation of misfolded proteins in ER, caus-
ing ER stress and activation of UPR. The results show
that TTA inhibits SW620 cell growth, at least partly, via
t h es a m em e c h a n i s m sa sD H A .T h u s ,c a n c e rc e l l ss e e m
to cope with stress induced by various FAs through the
same mechanisms.
Methods
Materials and cell culture
TTA was prepared at the Department of Chemistry,
University of Bergen, Norway, as described previously
[72] and in Supplementary experimental procedures
(Additional file 2). All other solvents were of reagent
grade from commercial sources. Antibody specifications
are found in Additional file 2. The human colon carci-
noma cell line SW620 was obtained from the American
Type Culture Collection (ATCC, Rockville, MD) and
cultivated in Leibovitz’sL - 1 5m e d i u m( C a m b r e x ,B i o -
Whittaker, Walkersville, MD) supplemented with L-glu-
tamine (2 mM), FBS (10%) and gentamicin (45 mg/l)
(complete growth medium), in a humidified atmosphere
of 5% CO2: 95% air at 37°C.
Cell proliferation assay by xCELLigence
SW620 cells were seeded in 16 well plates (E-plate 16,
Roche, Mannheim, Germany) (12.000 cells in 150 μl
medium/well), following the xCELLigence Real Time
Cell Analyzer (RTCA) DP instrument manual as pro-
vided by the manufacturer (Roche). After ~24 h, TTA
(75 μM, prepared as described in Additional file 2) or
the vehicle NaOH (control medium) was added, and the
experiment was allowed to run for 72 h. Average base-
line cell index and percent reduction of baseline cell
index for TTA-treated cells compared to control cells
were calculated for at least two measurements from 4
replicate experiments ± SD. Significance was calculated
using one-tailed Student’s t-test (P < 0.05).
RNA isolation, gene expression profiling and statistical
analysis
SW620 cells were seeded in 175 cm
2 flasks (3.5 × 10
6
cells in 28 ml medium). After 24 h incubation, cells
were treated with TTA (75 μM) or NaOH (control) for
24 h. Cell harvesting and total RNA isolation was per-
formed as elaborated in [28], using the High Pure RNA
Isolation Kit (Roche). Gene expression profiling was per-
formed following the Eukaryote expression manual from
Affymetrix (Santa Clara, CA), using the Human Genome
U133 2.0 Plus Array (Affymetrix), as described in Addi-
tional file 2. Statistical analysis of gene expression
results was performed using the RMA method. Differen-
tially expressed genes were identified using a linear
model with a modified T-statistic [73], and results were
corrected for multiple testing using the method
described in [74] with a false discovery rate of 0.05.
Annotations of probe sets and biological information of
genes were retrieved from the web-based NetAffx Ana-
lysis Center at affymetrix.com and eGOn at genetools.
no. Signal values presented are mean values of 3 repli-
cate experiments. All experiments have been submitted
to Array-Express with accession number E-MEXP-2590.
Western blot analysis
Cells were treated with TTA (75 μM) or NaOH for 3, 6,
12, 24 and/or 48 h, as described in the gene expression
profiling method. For detection of eIF2a-P and cyclin
D1, cells were harvested as elaborated in [28], and cyto-
solic protein extracts were prepared immediately in lysis
buffer as described in [63]. Nuclear protein extracts for
detection of ATF4, CHOP, TRIB3 and C/EBPb were
obtained by using Nuclear Extract Kit (Active Motif,
Rixensart, Belgium) according to the manufacturer’s
protocol. Protein concentrations were measured using
Bio-Rad Protein Assay (Bio-Rad, Hercules, CA), and the
protein extracts were snap-f r e e z e di nl i q u i dn i t r o g e n
and stored at -80°C until further use. Cytosolic and
nuclear proteins (80 or 50 μg per well, respectively)
were separated on 10% precast denaturing NuPAGE
®
gels (Invitrogen, Carlsbad, US) and transferred onto
Immobilon polyvinylidene difluoride membranes
Lundemo et al. Lipids in Health and Disease 2011, 10:190
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phosphate buffered saline buffer with 0.1% (v/v) Tween
®
20 (BioRad, Hercules, CA) and 5% blocker non-fat dry
milk, before incubated with primary and secondary
horse radish peroxidase-conjugated antibodies (DAKO,
Carpinteria, CA) dissolved in this blocking buffer as
described in Additional file 2. eIF2a-P incubations were
performed using tris-buffered saline Tween 20 buffer as
described in [63]. Blots were detected by chemilumines-
cense using SuperSignal
® West Femto Maximum Sensi-
tivity Substrate (Pierce, Rockford, IL) and visualized by
Kodak Image Station 4000R (Eastman Kodak Co.,
Rochester, NY). Western blot band intensities were
quantified using Kodak Molecular Imaging Software
(version 4.0.1). Quantified western blot results, based on
3 independent replicates, were analysed as described in
the proliferation assay method.
Additional material
Additional file 1: Supplementary gene expression results. Functional
categories of significantly differentially expressed transcripts affected in
SW620 cells treated with TTA (75 μM) for 24 h, as determined by
Affymetrix microarray analysis (P < 0.05).
Additional file 2: Supplementary experimental procedures. The file
contains supplementing information about the experimental procedures
including preparation of TTA stock solution and medium, gene
expression experiments and antibodies used.
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